Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000
Debt
Debt-to-Equity Ratio-3.20
Current Ratio4.03
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio-2.48
Forward P/E Ratio-3.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.18 million
Price / Sales19.10
Cash FlowN/A
Price / CashN/A
Book Value($0.31) per share
Price / Book-5.03
Profitability
EPS (Most Recent Fiscal Year)($0.63)
Net Income$-183,760,000.00
Net Margins-529.93%
Return on EquityN/A
Return on Assets-58.74%
Miscellaneous
Employees347
Outstanding Shares381,670,000
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $9.70 million for the quarter, compared to analyst estimates of $9.33 million. Novavax's revenue was up 70.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.16) earnings per share. View Novavax's Earnings History.
What price target have analysts set for NVAX?
8 brokerages have issued 12-month price objectives for Novavax's stock. Their predictions range from $1.35 to $10.00. On average, they expect Novavax's share price to reach $3.5125 in the next twelve months. View Analyst Ratings for Novavax.
What are Wall Street analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (5/15/2018)
- 2. Cantor Fitzgerald analysts commented, "NanoFlu seasonal flu vaccine could be just what the Dr. ordered. The mismatch of commercially available (egg-production-based) seasonal flu vaccines in the current season underscores the theoretical utility of NVAX’s vaccine production technology. Avoiding influenza virus propagation in eggs could reduce the need for egg adaptation and possible generation of virus particles that do not faithfully resemble the wild type viruses recommended by health organizations for inclusion in flu vaccines. Particularly when prevailing strains are highly pathogenic, e.g., H3N2, having a better matched flu vaccine would seem to be desirable, in our view." (3/15/2018)
Are investors shorting Novavax?
Novavax saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 49,824,245 shares, an increase of 2.0% from the May 15th total of 50,820,674 shares. Based on an average trading volume of 3,891,298 shares, the short-interest ratio is currently 12.8 days. Approximately 13.2% of the company's stock are sold short. View Novavax's Current Options Chain.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Repligen (RGEN), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Iovance Biotherapeutics (IOVA) and DBV Technologies (DBVT).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 70)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 58)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 52)
- Dr. Gregory M. Glenn, Pres of R&D (Age 64)
- Ms. Jill Hoyt, VP of HR & Admin.
Has Novavax been receiving favorable news coverage?
News stories about NVAX stock have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novavax earned a news impact score of 0.14 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.09 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Novavax's major shareholders?
Novavax's stock is owned by a number of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (1.86%), Millennium Management LLC (1.39%), Rock Springs Capital Management LP (0.72%), UBS Group AG (0.42%), Schwab Charles Investment Management Inc. (0.40%) and Chicago Equity Partners LLC (0.22%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.
Which major investors are selling Novavax stock?
NVAX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, JPMorgan Chase & Co., Federated Investors Inc. PA and Chicago Equity Partners LLC. View Insider Buying and Selling for Novavax.
Which major investors are buying Novavax stock?
NVAX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Rock Springs Capital Management LP, EAM Global Investors LLC, Russell Investments Group Ltd., Element Capital Management LLC, Jane Street Group LLC and Cubist Systematic Strategies LLC. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $1.56.
How big of a company is Novavax?
Novavax has a market capitalization of $591.60 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
